GleamWall
中文EN

CRVS Corvus Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1626971 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-326.6%
TTM EPS YoY-33.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-45.9%
ROA-42.3%
ROIC (approx.)-40.8%
Asset turnover—

Leverage & solvency

Liabilities / assets6.9%
Debt / equity0.00x
Current ratio13.38x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.73x
Accruals ratio-11.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$17.78M$15.96M$11.18M$9.94M$8.45M$7.87M$7.45M$5.97M
SG&A expense$3.58M$3.33M$3.70M$2.28M$2.12M$2.39M$2.47M$2.13M
Operating income-$21.36M-$19.30M-$14.88M-$12.22M-$10.57M-$10.26M-$9.92M-$8.11M
Pretax income-$19.45M-$17.25M-$13.09M-$11.61M-$9.83M-$7.61M$15.73M-$9.94M
Income tax$0$0$0$0$0$0$0$0
Net income-$20.34M-$17.96M-$13.69M-$12.32M-$10.16M-$8.00M$15.19M-$12.11M
EBITDA-$21.27M-$19.26M-$14.85M-$12.19M-$10.54M-$10.23M-$9.90M-$8.09M
EPS (basic)-0.22-0.19-0.15—-0.12-0.100.21—
EPS (diluted)-0.22-0.19-0.15—-0.12-0.10-0.13—
Weighted avg. shares (diluted)92.49M92.37M90.00M—82.84M77.77M75.15M—
Balance sheet
Cash & equivalents$15.01M$18.91M$40.10M$4.58M$2.87M$14.69M$5.00M$8.74M
Short-term investments$187.93M$196.32M$196.61M$52.17M———$43.22M
Receivables$5,000$6,000$43,000$37,000$32,000$86,000$79,000$75,000
Current assets$206.34M$220.97M$239.95M$58.21M$66.94M$75.78M$45.49M$54.41M
PP&E, net$801,000$830,000$282,000$220,000$221,000$249,000$165,000$151,000
Total assets$223.88M$239.27M$253.19M$71.12M$80.47M$89.46M$59.44M$68.91M
Current liabilities$15.42M$13.67M$12.11M$9.38M$8.07M$8.51M$9.28M$35.40M
Total liabilities$15.56M$13.95M$12.52M$9.91M$8.71M$9.23M$10.11M$36.34M
Shareholders' equity$208.32M$225.33M$240.68M$61.20M$71.77M$80.23M$49.33M$32.57M
Shares outstanding84.32M84.12M84.09M74.70M74.68M74.51M68.17M67.90M
Cash flow statement
Operating cash flow-$12.21M-$15.40M-$10.37M-$9.19M-$9.57M-$5.78M-$8.26M-$8.46M
Capital expenditure$66,000$582,000$91,000$25,000$0$113,000$36,000—
Free cash flow-$12.28M-$15.98M-$10.46M-$9.22M-$9.57M-$5.89M-$8.30M—
Investing cash flow$7.52M-$5.96M-$144.85M$10.88M-$2.62M-$20.30M$4.24M-$6.08M
Financing cash flow$805,000$166,000$190.75M$20,000$360,000$35.77M$279,000$18.61M
Depreciation & amortization$95,000$34,000$29,000$26,000$28,000$29,000$22,000$20,000
Stock-based compensation$2.83M$2.61M$2.65M$1.57M$1.25M$1.26M$1.25M$813,000

Free plan shows the latest 8 periods; Pro shows all 47 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.